All In Biotech

Drug Trial Radar · NCT04051268

Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Non-inferiority to PQed (Prequalified) TCV (Typhoid Conjugate Vaccine)

Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,071 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,071

Actual

Start

Mar 2, 2020

Primary completion

Nov 24, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
PT Bio FarmaIndustry
Sponsor type
Industry
First posted
Aug 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.

Conditions

  • Safety Issues
  • Immunogenicity

Interventions

  • Vi-DT Typhoid Conjugate VaccineBiological

    1 dose of Investigational Product

  • PQed Typhoid Conjugate VaccineBiological

    1 dose of Active Comparator

  • Vi Polysaccharide VaccineBiological

    1 dose of Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ImmunogenicityTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jatinegara Primary Health Care

    Jakarta, Jakart, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.